Last 48 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
BrainsWay Ltd.'s quarterly P/E stands at 27.7x, down 53.3% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 27.2% YoY to 20.4x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 41.36 | 27.69 | 16.98 | 47.13 | 32.90 | 59.25 | 28.64 | 28.88 | 38.00 | 200.76 | 207.69 | — | — |
| — | -53.3% | -40.7% | +63.2% | -13.4% | -70.5% | -86.2% | — | — | — | — | — | — | |
| P/S Ratio | 11.18 | 4.08 | 3.43 | 5.30 | 4.92 | 3.79 | 3.89 | 3.67 | 2.53 | 2.42 | 2.98 | 2.02 | 1.21 |
| — | +7.7% | -11.9% | +44.5% | +94.4% | +56.4% | +30.4% | +81.7% | +109.7% | +121.0% | +75.6% | -30.1% | -51.5% | |
| P/B Ratio | 4.31 | 3.35 | 2.72 | 4.09 | 3.65 | 2.74 | 2.85 | 3.50 | 2.36 | 2.10 | 2.59 | 1.63 | 0.91 |
| — | +22.0% | -4.5% | +16.8% | +54.8% | +30.7% | +10.0% | +115.2% | +157.8% | +210.1% | +186.9% | +33.1% | -38.5% | |
| P/FCF | 35.61 | 157.72 | 96.06 | 122.26 | 5.54 | 11.02 | 17.27 | 39.40 | 50.56 | 8.98 | 13.25 | 19.91 | — |
| — | +1330.9% | +456.2% | +210.3% | -89.0% | +22.7% | +30.3% | +97.9% | — | — | — | — | — | |
| EV / EBITDA | 89.26 | 20.41 | 15.26 | 33.63 | 48.36 | 28.06 | 24.99 | 36.35 | 16.28 | 46.22 | 2.34 | 29.10 | — |
| — | -27.2% | -38.9% | -7.5% | +197.1% | -39.3% | +968.9% | +24.9% | — | — | — | — | — | |
| EV / EBIT | 121.01 | 18.48 | 11.65 | 23.42 | 16.22 | 14.71 | 41.80 | 23.85 | 13.03 | 26.65 | 19.61 | — | — |
| — | +25.6% | -72.1% | -1.8% | +24.4% | -44.8% | +113.2% | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
BrainsWay Ltd.'s operating margin was 12.9% in Q1 2026, down 0.3 pp QoQ and up 7.9 pp YoY. The trailing four-quarter average of 10.0% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.4% | 75.2% | 76.4% | 75.2% | 75.2% | 74.6% | 74.6% | 73.5% | 75.3% | 74.9% | 74.6% | 74.3% | 73.2% |
| — | +0.7% | +2.5% | +2.3% | -0.2% | -0.4% | -0.1% | -1.1% | +2.9% | +2.7% | +4.6% | +0.4% | +0.9% | |
| Operating Margin | 8.3% | 12.9% | 13.2% | 9.3% | 4.6% | 5.0% | 3.8% | 2.7% | 5.9% | 1.0% | 111.9% | -1.6% | -17.2% |
| — | +158.6% | +248.8% | +246.6% | -21.9% | +388.3% | -96.6% | +267.0% | +134.1% | +101.8% | +256.1% | +98.3% | +31.6% | |
| Net Margin | 14.6% | 14.7% | 20.2% | 11.6% | 16.0% | 9.6% | 13.6% | 6.3% | 6.0% | 1.2% | 1.4% | -2.8% | -21.2% |
| — | +53.7% | +48.7% | +83.9% | +167.6% | +686.2% | +864.2% | +327.5% | +128.2% | +103.3% | +102.2% | +97.2% | +30.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.3% | 3.1% | 4.1% | 2.3% | 3.1% | 1.8% | 2.9% | 1.5% | 1.4% | 0.3% | 0.3% | -0.6% | -3.9% |
| — | +75.0% | +40.6% | +48.9% | +117.7% | +561.3% | +849.0% | +373.1% | +135.8% | +104.8% | +103.7% | +94.3% | +11.9% | |
| ROA | 7.4% | 2.0% | 2.6% | 1.4% | 1.9% | 1.1% | 1.9% | 1.0% | 0.9% | 0.2% | 0.2% | -0.4% | -2.7% |
| — | +75.0% | +39.5% | +45.0% | +108.6% | +556.8% | +799.2% | +348.7% | +133.4% | +104.5% | +103.5% | +94.7% | +18.8% | |
| ROIC | 59.3% | 8.3% | 15.4% | 14.8% | 21.3% | — | — | — | 3.0% | 0.2% | 52.5% | — | — |
| — | — | — | — | +599.6% | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
BrainsWay Ltd.'s Debt/EBITDA ratio is 2.7x, down from 3.0x last quarter — at a moderate level that warrants monitoring. The current ratio has weakened 33.6% YoY to 3.34x, tightening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.09 | 0.10 | 0.09 | 0.09 | 0.09 | — | 0.10 | — | 0.01 | — | — |
| — | +1.4% | +3.2% | — | -11.5% | — | +696.8% | — | — | — | +5.4% | — | — | |
| Debt / EBITDA | 1.16 | 2.71 | 3.01 | 4.07 | 6.35 | 5.74 | 4.94 | — | 4.94 | — | 0.05 | — | — |
| — | -52.7% | -39.1% | — | +28.5% | — | +10845.6% | — | — | — | — | — | — | |
| Current Ratio | 3.83 | 3.34 | 3.83 | 3.19 | 3.51 | 5.03 | 5.19 | 4.52 | 4.70 | 4.48 | 5.68 | 6.36 | 6.98 |
| — | -33.6% | -26.2% | -29.4% | -25.4% | +12.3% | -8.6% | -28.9% | -32.7% | -26.9% | -20.4% | -7.1% | -9.4% | |
| Quick Ratio | 3.51 | 3.04 | 3.51 | 3.02 | 3.34 | 4.75 | 4.90 | 4.23 | 4.39 | 4.18 | 5.30 | 5.94 | 6.54 |
| — | -36.0% | -28.4% | -28.6% | -23.9% | +13.7% | -7.5% | -28.8% | -32.8% | -25.5% | -20.4% | -8.4% | -12.0% | |
| Interest Coverage | 4.45 | 8.55 | 6.85 | — | 3.67 | 3.16 | 3.91 | 2.97 | 2.75 | 1.66 | 7.78 | -0.62 | -1.56 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BWAY stock.
BrainsWay Ltd.'s current P/E is 41.4x. The average P/E over the last 4 quarters is 31.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BrainsWay Ltd.'s current operating margin is 8.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BrainsWay Ltd.'s business trajectory between earnings reports.